| scholarly article | Q13442814 |
| P50 | author | Peter Lichter | Q2076661 |
| Michael Hallek | Q20752664 | ||
| Thorsten Zenz | Q46329248 | ||
| Stephan Stilgenbauer | Q47158807 | ||
| Hartmut Döhner | Q66385451 | ||
| Konstanze Döhner | Q66385457 | ||
| P2093 | author name string | Mario Cazzola | |
| Lin Wu | |||
| Andreas Bühler | |||
| Dirk Winkler | |||
| Jennifer Edelmann | |||
| Lars Bullinger | |||
| Manuela Bergmann | |||
| Peter Paschka | |||
| Raymonde Busch | |||
| Michael Kneba | |||
| Günter Fingerle-Rowson | |||
| Ulrich Jäger | |||
| Daniel Mertens | |||
| Eugen Tausch | |||
| Sebastian Böttcher | |||
| Kirsten Fischer | |||
| Matthias Ritgen | |||
| Clemens M Wendtner | |||
| Andrea Schnaiter | |||
| Marianna Rossi | |||
| Nancy Patten | |||
| Michael K Wenger | |||
| Patrick Hoth | |||
| Anna M Fink | |||
| Sabrina Kless | |||
| Silja Mack | |||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| lymphocyte | Q715347 | ||
| chronic lymphocytic leukemia | Q1088156 | ||
| P304 | page(s) | 3247-3254 | |
| P577 | publication date | 2014-03-20 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. | |
| P478 | volume | 123 |
| Q37542431 | A Novel Assay for the Identification of NOTCH1 PEST Domain Mutations in Chronic Lymphocytic Leukemia |
| Q35984259 | A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia |
| Q92623012 | A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma |
| Q33880538 | A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia |
| Q33709543 | An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness |
| Q50569242 | Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia. |
| Q36471596 | Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia |
| Q89090793 | B-cell receptor stereotypy and chronic lymphocytic leukaemia |
| Q92351211 | Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia |
| Q40784167 | CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. |
| Q59126180 | Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia |
| Q37641736 | Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells |
| Q33862792 | Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks |
| Q39263974 | Chronic lymphocytic leukaemia genomics and the precision medicine era. |
| Q52836247 | Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. |
| Q91666607 | Chronic lymphocytic leukaemia: from genetics to treatment |
| Q38675358 | Chronic lymphocytic leukemia (CLL)-Then and now. |
| Q36826893 | Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015 |
| Q38663689 | Clinical Impact of the 2016 Update to the WHO Lymphoma Classification |
| Q38744632 | Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia |
| Q27853333 | Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. |
| Q27027493 | Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond |
| Q89518987 | Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial |
| Q26783600 | Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia |
| Q39406673 | Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms |
| Q33648906 | Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients |
| Q64123404 | Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia |
| Q38262761 | Clonal evolution in chronic lymphocytic leukemia: impact of subclonality on disease progression |
| Q89776891 | Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL |
| Q42291852 | Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia |
| Q40301879 | Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia |
| Q26823586 | Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution |
| Q64092413 | Deep targeted sequencing of in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment |
| Q52684522 | Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase II study. |
| Q35653850 | Developing Molecular Signatures for Chronic Lymphocytic Leukemia |
| Q91771804 | Diabetes Mellitus Is Associated with Inferior Prognosis in Patients with Chronic Lymphocytic Leukemia: A Propensity Score-Matched Analysis |
| Q33774491 | Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood |
| Q48618984 | Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib |
| Q40455172 | EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia. |
| Q50146313 | ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation |
| Q39324849 | ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia |
| Q89777617 | Early progression of disease as a predictor of survival in chronic lymphocytic leukemia |
| Q58585095 | Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials |
| Q54108755 | Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy. |
| Q39028378 | Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. |
| Q48310393 | Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. |
| Q37260520 | Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations |
| Q64092443 | First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013 |
| Q88968433 | Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study |
| Q35741703 | Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans |
| Q47359917 | Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis |
| Q52685587 | Frontline Therapy of CLL: Evolving Treatment Paradigm. |
| Q46339557 | Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia |
| Q38819164 | Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets |
| Q94482236 | Genetics of "high-risk" chronic lymphocytic leukemia in the times of chemoimmunotherapy |
| Q28087672 | Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia |
| Q30833823 | Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome |
| Q36782516 | Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib |
| Q38418199 | High-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia: a systematic review |
| Q88645380 | How and when I do allogeneic transplant in CLL |
| Q90466660 | IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a Danish nationwide population-based study |
| Q38956893 | Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study |
| Q33419580 | Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial |
| Q38545545 | Ibrutinib in B lymphoid malignancies |
| Q90315525 | Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial |
| Q92314359 | Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia |
| Q33438825 | Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial |
| Q28077136 | Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy |
| Q47610804 | Impact of Fluorescent In Situ Hybridization Aberrations and CLLU1 Expression on the Prognosis of Chronic Lymphocytic Leukemia: Presentation of 156 Patients from Turkey. |
| Q42923891 | Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go? |
| Q36326271 | Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing? |
| Q48248056 | Lamin B1 regulates somatic mutations and progression of B-cell malignancies. |
| Q31056968 | Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. |
| Q89770415 | Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG) |
| Q92176355 | Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab |
| Q36884141 | Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease |
| Q41095380 | Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience |
| Q33869257 | MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer |
| Q52675362 | Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia. |
| Q49692075 | Management of high risk chronic lymphocytic leukaemia (CLL) patients in Australia |
| Q39169789 | Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia |
| Q39214379 | Milestones in Chronic Lymphocytic Leukemia: An exciting decade of progress-10th anniversary of memo |
| Q33913537 | Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups |
| Q33729711 | Molecular Testing of Lymphoproliferative Disorders: Current Status and Perspectives |
| Q38335695 | Molecular pathogenesis of CLL and its evolution |
| Q36550468 | Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia |
| Q39714436 | Mutations driving CLL and their evolution in progression and relapse |
| Q60358020 | Mutations in the 3′ untranslated region of NOTCH1 are associated with low CD20 expression levels chronic lymphocytic leukemia |
| Q55668973 | NOTCH1 Aberrations in Chronic Lymphocytic Leukemia. |
| Q52638918 | NOTCH1 mutation and its prognostic significance in Chinese chronic lymphocytic leukemia: a retrospective study of 317 cases. |
| Q48140340 | NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types. |
| Q52931736 | NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. |
| Q54345184 | NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. |
| Q51093052 | NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components. |
| Q37621653 | Non-coding NOTCH1 mutations in chronic lymphocytic leukemia; their clinical impact in the UK CLL4 trial. |
| Q93040664 | Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells |
| Q88636732 | Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study |
| Q92914129 | Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study |
| Q47582687 | Optimizing frontline therapy of CLL based on clinical and biological factors. |
| Q60920978 | Overview of non-coding mutations in chronic lymphocytic leukemia |
| Q91842078 | Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL |
| Q41552505 | Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions |
| Q37410709 | Patients' Preferences for Genomic Diagnostic Testing in Chronic Lymphocytic Leukaemia: A Discrete Choice Experiment |
| Q90690181 | Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia |
| Q35958056 | Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia |
| Q90270152 | Precision Medicine Management of Chronic Lymphocytic Leukemia |
| Q92413642 | Predicting the outcome of patients with chronic lymphocytic leukemia: Progress and uncertainty |
| Q33714743 | Predicting treatment outcomes in CLL. |
| Q38997367 | Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia |
| Q47276117 | Prenatal diagnosis of sex chromosomal inversion, translocation and deletion |
| Q38345576 | Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma |
| Q87856666 | Prognostic Factors in the Era of Targeted Therapies in CLL |
| Q89600801 | Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry |
| Q24186840 | Prognostic models for chronic lymphocytic leukaemia: an exemplar systematic review and meta-analysis |
| Q92169106 | Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations |
| Q30240258 | Prognostication of chronic lymphocytic leukemia in the era of new agents |
| Q49788400 | Proteomics profiling of CLL versus healthy B-cells identifies putative therapeutic targets and a subtype-independent signature of spliceosome dysregulation |
| Q46318389 | Recent therapeutic advances in chronic lymphocytic leukemia |
| Q30235460 | Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice |
| Q27853022 | Recurrent mutations refine prognosis in chronic lymphocytic leukemia. |
| Q40708030 | Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia (CLL) patients with the aberration of p53 gene |
| Q57053852 | Renal involvement in chronic lymphocytic leukemia |
| Q89562799 | Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm |
| Q90589544 | Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials |
| Q30249283 | Richter transformation of CLL. |
| Q50025029 | Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in no |
| Q50889845 | Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells. |
| Q42378392 | SF3B1 mutation is a prognostic factor in chronic lymphocytic leukemia: a meta-analysis |
| Q64983614 | Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. |
| Q92615045 | Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia |
| Q50044415 | Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience |
| Q59137780 | Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies |
| Q38922539 | Somatic TP53 Mutations in the Era of Genome Sequencing. |
| Q38289057 | Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy |
| Q42208521 | Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation |
| Q59797087 | TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics |
| Q35146301 | Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting |
| Q50074751 | Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome |
| Q91283886 | Telomere length predicts for outcome to FCR chemotherapy in CLL |
| Q38986156 | The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression |
| Q59808738 | The NOTCH Pathway and Its Mutations in Mature B Cell Malignancies |
| Q64263185 | The Treatment of Chronic Lymphatic Leukemia |
| Q59413072 | The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial) |
| Q26749214 | The clinical implications of gene mutations in chronic lymphocytic leukaemia |
| Q38286344 | The genomic landscape of chronic lymphocytic leukaemia: biological and clinical implications |
| Q34710882 | The genomic landscape of chronic lymphocytic leukemia: clinical implications |
| Q40562742 | The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases |
| Q38748645 | The molecular pathogenesis of chronic lymphocytic leukaemia |
| Q49989104 | The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment |
| Q26775506 | The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia |
| Q37638782 | The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies |
| Q38719429 | The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia |
| Q101051264 | Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients |
| Q90465397 | Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study |
| Q34625543 | Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies? |
| Q64958039 | Treatment Outcomes of Novel Targeted Agents in Relapse/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-Analysis. |
| Q38573785 | Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading? |
| Q41310328 | Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis |
| Q39038037 | Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies. |
| Q54309968 | [Chronic lymphocytic leukemia: current standards and novel approaches]. |
Search more.